The study by Wei and co-workers also demonstrated that the anti-tumor activity of anti-PD-1 immunotherapy was enhanced by oral treatment of live LGG through boosting tumor-infiltrating DCs and CD8+ T cells (30). The gene discussed is PDCD1; the disease is neoplasm.